ITCI Intra-Cellular Therapies, Inc. Stock Quote

ITCI [NASD]

Index	-	P/E	-	EPS (ttm)	-3.20	Insider Own	1.40%	Shs Outstand	81.36M	Perf Week	4.12%
Market Cap	3.59B	Forward P/E	-	EPS next Y	-3.02	Insider Trans	-30.14%	Shs Float	74.44M	Perf Month	-11.49%
Income	-259.10M	PEG	-	EPS next Q	-1.00	Inst Own	81.10%	Short Float	6.09%	Perf Quarter	-0.54%
Sales	70.60M	P/S	50.84	EPS this Y	-20.50%	Inst Trans	0.37%	Short Ratio	4.65	Perf Half Y	18.06%
Book/sh	5.98	P/B	7.13	EPS next Y	8.10%	ROA	-40.30%	Target Price	60.89	Perf Year	28.03%
Cash/sh	5.67	P/C	7.52	EPS next 5Y	-	ROE	-44.90%	52W Range	28.40 - 55.19	Perf YTD	-18.49%
Dividend	-	P/FCF	-	EPS past 5Y	-2.10%	ROI	-35.20%	52W High	-22.71%	Beta	1.28
Dividend %	-	Quick Ratio	10.50	Sales past 5Y	201.60%	Gross Margin	90.60%	52W Low	50.21%	ATR	3.36
Employees	383	Current Ratio	10.70	Sales Q/Q	200.00%	Oper. Margin	-	RSI (14)	49.30	Volatility	7.97% 6.85%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-19.10%	Profit Margin	-	Rel Volume	2.74	Prev Close	38.87
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Nov 09 BMO	Payout	-	Avg Volume	976.10K	Price	42.66
Recom	1.60	SMA20	-6.96%	SMA50	0.68%	SMA200	11.30%	Volume	2,675,431	Change	9.75%

Sep-23-21

Initiated

Needham

Buy

$55

Dec-15-20

Initiated

BofA Securities

Buy

$40

Dec-10-20

Initiated

Goldman

Buy

$38

Feb-20-20

Initiated

Evercore ISI

Outperform

Jan-31-20

Downgrade

JP Morgan

Overweight → Neutral

$26

Dec-24-19

Reiterated

Canaccord Genuity

Buy

$29 → $65

Aug-12-19

Initiated

Jefferies

Buy

$16

Feb-26-18

Initiated

JP Morgan

Overweight

Feb-08-18

Initiated

RBC Capital Mkts

Outperform

$33

Dec-15-17

Initiated

Canaccord Genuity

Buy

$31

Nov-08-17

Upgrade

SunTrust

Hold → Buy

Sep-07-17

Upgrade

Piper Jaffray

Neutral → Overweight

Aug-30-17

Upgrade

Ladenburg Thalmann

Neutral → Buy

Aug-24-17

Upgrade

JMP Securities

Mkt Perform → Mkt Outperform

Aug-23-17

Upgrade

Leerink Partners

Mkt Perform → Outperform

May-02-17

Downgrade

Leerink Partners

Outperform → Mkt Perform

May-02-17

Downgrade

Ladenburg Thalmann

Buy → Neutral

May-01-17

Downgrade

Piper Jaffray

Overweight → Neutral

Dec-16-16

Initiated

Cantor Fitzgerald

Overweight

Sep-29-16

Reiterated

RBC Capital Mkts

Outperform

$74 → $49

Jan-10-22 05:38PM	Penbrook Management LLC Buys Cohu Inc, Kulicke & Soffa Industries Inc, PubMatic Inc, Sells ... GuruFocus.com
Jan-07-22 04:01PM	Intra-Cellular Therapies Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire -5.14%
Jan-04-22 10:05PM	Intra-Cellular Therapies Prices Public Offering of Common Stock GlobeNewswire -14.11%
05:55PM	Why Intra-Cellular Therapies Took a Big Hit Today Motley Fool
Jan-03-22 04:01PM	Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock GlobeNewswire
08:00AM	Intra-Cellular Therapies to Present at the 40th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-27-21 11:38PM	Advisors' Inner Circle Fund III Buys SPDR Biotech ETF, Scientific Games Corp, Silvergate ... GuruFocus.com
Dec-24-21 09:15AM	Intra-cellular Therapies Inc (ITCI) SVP of Finance CFO Lawrence J. Hineline Sold $8. ... GuruFocus.com
Dec-23-21 10:32AM	3 Strong Buy Stocks Showing Monster Growth TipRanks
Dec-21-21 09:18AM	Company News for Dec 21, 2021 Zacks +6.28%
Dec-20-21 08:59AM	FDA Approves Intra-Cellular's Antipsychotic For Bipolar Depression Benzinga +15.81%
06:47AM	Intra-Cellular Therapies Announces U.S. FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression in Adults GlobeNewswire
Dec-14-21 06:56AM	Shareholders have faith in loss-making Intra-Cellular Therapies (NASDAQ:ITCI) as stock climbs 3.4% in past week, taking three-year gain to 183% Simply Wall St.
Dec-08-21 07:38PM	Tekla Life Sciences Investors Buys Amgen Inc, Alkermes PLC, Novavax Inc, Sells Moderna Inc, ... GuruFocus.com
Dec-06-21 04:01PM	Intra-Cellular Therapies Mourns the Passing of Director, Dr. Richard Lerner GlobeNewswire
Nov-09-21 02:00PM	Intra-Cellular Therapies inc (ITCI) Q3 2021 Earnings Call Transcript Motley Fool
08:45AM	Intra-Cellular Therapies (ITCI) Reports Q3 Loss, Tops Revenue Estimates Zacks
07:30AM	Intra-Cellular Therapies Reports Third Quarter 2021 Financial Results and Provides Corporate Update GlobeNewswire
Nov-02-21 08:00AM	Intra-Cellular Therapies to Host Third Quarter 2021 Financial Results Conference Call and Webcast GlobeNewswire
Nov-01-21 03:01PM	Analysts Estimate Intra-Cellular Therapies (ITCI) to Report a Decline in Earnings: What to Look Out for Zacks +6.18%
Oct-26-21 10:26AM	Hedge Funds Are Warming Up To Intra-Cellular Therapies Inc (ITCI) Insider Monkey
Oct-19-21 07:30PM	The Most Disruptive Energy And Healthcare Stocks Of The Year Oilprice.com
Oct-18-21 08:00AM	Intra-Cellular Therapies Announces Amended Start Time to Virtual Event on Wednesday, October 20 GlobeNewswire +6.08%
Oct-08-21 08:00AM	Intra-Cellular Therapies to Host a Virtual Event to Feature Highlights of Several of its Development Programs GlobeNewswire
Sep-28-21 09:28AM	Company News for Sep 28, 2021 Zacks
Sep-27-21 09:19AM	Intra-Cellular says clinical study shows its schizophrenia drug helps patients with bipolar disorder MarketWatch
07:30AM	Intra-Cellular Therapies Announces Publication of Lumateperone Pivotal Phase 3 Study in Bipolar Depression in The American Journal of Psychiatry GlobeNewswire
Sep-22-21 08:00AM	Intra-Cellular Therapies to Present at the 2021 Cantor Virtual Global Healthcare Conference GlobeNewswire
Sep-21-21 01:21PM	Should You Consider Investing in Intra-Cellular Therapies (ITCI)? Insider Monkey +5.33%
Sep-20-21 07:30AM	Intra-Cellular Therapies Announces Publications Highlighting Beneficial Effects of Phosphodiesterase Type I Inhibition with Lenrispodun (ITI-214) on Cardiovascular Function in Patients with Heart Failure and in Models of Accelerated Aging GlobeNewswire
Aug-16-21 08:52AM	Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Good Position To Deliver On Growth Plans Simply Wall St.
Aug-13-21 04:48PM	Why Intra-Cellular Therapies Was Weak This Week Motley Fool
Aug-10-21 08:00AM	Intra-Cellular Therapies to Present at the Canaccord Genuity 41st Annual Growth Conference GlobeNewswire -8.80%
Aug-09-21 06:00PM	Intra-Cellular Therapies inc (ITCI) Q2 2021 Earnings Call Transcript Motley Fool -5.37%
09:05AM	Intra-Cellular Therapies (ITCI) Reports Q2 Loss, Tops Revenue Estimates Zacks
07:30AM	Intra-Cellular Therapies Reports Second Quarter 2021 Financial Results and Provides Corporate Update GlobeNewswire
Aug-02-21 03:01PM	Will Intra-Cellular Therapies (ITCI) Report Negative Q2 Earnings? What You Should Know Zacks
08:00AM	Intra-Cellular Therapies to Host Second Quarter 2021 Financial Results Conference Call and Webcast GlobeNewswire
Jun-19-21 02:44PM	Investors Who Bought Etherstack (ASX:ESK) Shares Five Years Ago Are Now Up 555% Simply Wall St.
Jun-15-21 01:04AM	Here's Why We Think Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) CEO Compensation Looks Fair for the time being Simply Wall St.
Jun-07-21 08:00AM	CAPLYTA® (lumateperone) Schizophrenia Safety and Tolerability Profile Published in the Journal, International Clinical Psychopharmacology GlobeNewswire +5.11%
May-26-21 08:00AM	Intra-Cellular Therapies to Present at Two Upcoming Investor Conferences GlobeNewswire
May-10-21 03:00PM	Intra-Cellular Therapies Inc (ITCI) Q1 2021 Earnings Call Transcript Motley Fool
08:45AM	Intra-Cellular Therapies (ITCI) Reports Q1 Loss, Tops Revenue Estimates Zacks
07:30AM	Intra-Cellular Therapies Reports First Quarter 2021 Financial Results and Provides Corporate Update GlobeNewswire
06:45AM	Intra-Cellular Therapies, Inc. to Host Earnings Call ACCESSWIRE
May-05-21 08:00AM	Intra-Cellular Therapies to Present at Two Upcoming Investor Conferences GlobeNewswire
May-04-21 08:00AM	Intra-Cellular Therapies to Host First Quarter 2021 Financial Results Conference Call and Webcast GlobeNewswire -8.03%
May-03-21 07:30AM	Intra-Cellular Therapies Announces FDA Acceptance of CAPLYTA® (lumateperone) sNDAs for the Treatment of Bipolar Depression GlobeNewswire
Apr-29-21 05:06PM	Earnings Preview: Intra-Cellular Therapies (ITCI) Q1 Earnings Expected to Decline Zacks
Apr-24-21 08:47AM	Is ITCI Stock A Buy or Sell? Insider Monkey
Apr-23-21 03:40AM	Breakeven On The Horizon For Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Simply Wall St.
Apr-22-21 07:30AM	Intra-Cellular Therapies Announces Investor Webcast and Presentations on Lumateperone Programs at the Upcoming American Psychiatric Association (APA) Annual Meeting GlobeNewswire
Apr-20-21 07:00AM	Intra-Cellular Therapies Announces Board of Director Nominations in Advance of 2021 Annual Meeting GlobeNewswire
Apr-12-21 07:30AM	Intra-Cellular Therapies Presents Data on Antitumor Effects of Phosphodiesterase I Inhibition in a Preclinical Colorectal Cancer Model at the 2021 American Association for Cancer Research (AACR) Annual Meeting GlobeNewswire
Feb-25-21 08:30PM	Intra-Cellular Therapies Inc (ITCI) Q4 2020 Earnings Call Transcript Motley Fool -5.71%
07:30AM	Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2020 Financial Results And Provides Corporate Update GlobeNewswire
06:30AM	Intra-Cellular Therapies, Inc. to Host Earnings Call ACCESSWIRE
Feb-24-21 10:42AM	Intra-Cellular Therapies Discloses New Drug Candidate For Dementia Related Episodes Benzinga
07:30AM	Intra-Cellular Therapies Announces Expansion of its Pipeline with the Introduction of a New Molecular Entity, ITI-1284 GlobeNewswire
Feb-22-21 08:00AM	Intra-Cellular Therapies Applies for FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression GlobeNewswire
Feb-19-21 08:00AM	Intra-Cellular Therapies to Present at the SVB Leerink 10th Annual Global Healthcare Conference GlobeNewswire
Feb-17-21 08:00AM	Intra-Cellular Therapies to Host Fourth Quarter and Full-Year 2020 Financial Results Conference Call and Webcast GlobeNewswire
Feb-10-21 02:58AM	Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Good Position To Deliver On Growth Plans Simply Wall St.
Jan-21-21 08:00AM	CAPLYTA® (lumateperone) Open-Label Safety Switching Study in Patients with Schizophrenia Published in the Journal, Schizophrenia Research GlobeNewswire
Jan-06-21 08:40AM	Do Options Traders Know Something About Intra-Cellular Therapies (ITCI) Stock We Don't? Zacks
Jan-05-21 08:00AM	Intra-Cellular Therapies to Present at the 39th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-29-20 08:00AM	Intra-Cellular Therapies Announces the Initiation of Clinical Trials for ITI-LLAI, a Long-Acting Injectable Formulation of Lumateperone for the Treatment of Schizophrenia and for ITI-333, a Novel Treatment for Opioid Use Disorder GlobeNewswire
Dec-14-20 01:58PM	Intra-Cellular Therapies Getting Closer To Key Technical Benchmark Investor's Business Daily
Dec-09-20 08:00AM	Intra-Cellular Therapies Highlights Lumateperone Presentations at the 59th Annual Meeting of the American College of Neuropsychopharmacology GlobeNewswire
Dec-01-20 05:32AM	2 Underrated Biotech Stocks to Buy Now Motley Fool
Nov-30-20 08:00AM	Intra-Cellular Therapies to Present at the Evercore ISI 3rd Annual HealthCONx Conference GlobeNewswire -5.36%
Nov-12-20 06:09AM	Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates Simply Wall St.
Nov-09-20 06:00PM	Intra-Cellular Therapies Inc (ITCI) Q3 2020 Earnings Call Transcript Motley Fool +8.99%
08:45AM	Intra-Cellular Therapies (ITCI) Reports Q3 Loss, Tops Revenue Estimates Zacks
08:19AM	Recap: Intra-Cellular Therapies Q3 Earnings Benzinga
07:30AM	Intra-Cellular Therapies Reports Third Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire
06:30AM	Intra-Cellular Therapies, Inc. to Host Earnings Call ACCESSWIRE
Nov-07-20 07:04AM	Got $1,000? You Could Double Your Money by Investing in These 2 Biotechs Motley Fool
Nov-04-20 08:00AM	Intra-Cellular Therapies to Host Third Quarter 2020 Financial Results Conference Call and Webcast GlobeNewswire +10.66%
Oct-26-20 08:18AM	Is Intra-Cellular Therapies' (NASDAQ:ITCI) 195% Share Price Increase Well Justified? Simply Wall St.
Oct-04-20 06:20AM	2 Top Biotech Stocks to Buy in October Motley Fool
Oct-02-20 07:00AM	New Ventures Funds Rebrands as Scientia Ventures PR Newswire -7.50%
Oct-01-20 04:30PM	Intra-Cellular Therapies Announces the Appointment of Dr. Suresh Durgam as Chief Medical Officer GlobeNewswire
Sep-22-20 11:08AM	Does This Pharma Company's Lead Asset Make it a Buy Today? Motley Fool -5.58%
Sep-15-20 08:00AM	Intra-Cellular Therapies to Present at the Morgan Stanley 18th Annual Global Healthcare Conference GlobeNewswire
Sep-14-20 08:00AM	Intra-Cellular Therapies to Present at the Cantor Virtual Global Healthcare Conference GlobeNewswire +10.31%
Sep-11-20 08:42AM	What Kind Of Investors Own Most Of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)? Simply Wall St. -10.89%
Sep-10-20 08:30PM	Intra-Cellular Therapies Prices Public Offering of Common Stock GlobeNewswire
01:38PM	Stick With the Intra-Cellular Rally for Another 25% Upside, Says Analyst TipRanks
Sep-09-20 05:12PM	Nasdaq Soars Nearly 300 Points as Intra-Cellular Breaks Through; a Lemon for Lululemon? Motley Fool +72.87%
04:16PM	Positive Test Results For Bipolar Treatment Sends Intra-Cellular Stock Soaring Investor's Business Daily
04:01PM	Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock GlobeNewswire
12:19PM	Why Intra-Cellular Therapies Stock Is Skyrocketing Today Motley Fool
09:08AM	ROCE Insights For Intra-Cellular Therapies Benzinga
07:00AM	Intra-Cellular Therapies Announces Positive Topline Results from Study 402 Evaluating Lumateperone as Adjunctive Therapy in Patients with Bipolar Depression GlobeNewswire
Sep-03-20 08:12AM	Implied Volatility Surging for Intra-Cellular Therapies (ITCI) Stock Options Zacks
Aug-10-20 05:30PM	Intra-Cellular Therapies Inc (ITCI) Q2 2020 Earnings Call Transcript Motley Fool -6.93%
08:45AM	Intra-Cellular Therapies (ITCI) Reports Q2 Loss, Misses Revenue Estimates Zacks
07:56AM	Recap: Intra-Cellular Therapies Q2 Earnings Benzinga

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also developing lumateperone, which is in Phase 3 clinical trials for the treatment of bipolar depression, as well as to treat autism spectrum disorder, and sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing ITI-002 that inhibits the enzyme phosphodiesterase type 1; ITI-214 for the treatment of Parkinson's disease and heart failure; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333, for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. is headquartered in New York, New York.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Durgam Suresh K.	Chief Medical Officer	Jan 18	Sale	42.03	6,223	261,553	23,104	Jan 20 04:07 PM
Durgam Suresh K.	Chief Medical Officer	Jan 10	Sale	40.76	6,870	280,020	29,327	Jan 11 08:08 PM
Neumann Mark	EVP, Chief Commercial Officer	Jan 10	Sale	40.78	20,948	854,255	45,339	Jan 11 08:06 PM
Halstead Michael	EVP and General Counsel	Jan 10	Sale	40.77	19,639	800,774	0	Jan 11 08:04 PM
Hineline Lawrence J.	SVP of Finance CFO	Jan 10	Sale	40.76	19,639	800,420	0	Jan 11 08:02 PM
Mates Sharon	Chairman, President & CEO	Jan 10	Sale	40.78	41,896	1,708,429	1,094,467	Jan 11 08:00 PM
Hineline Lawrence J.	SVP of Finance CFO	Dec 21	Option Exercise	16.81	175,000	2,941,951	175,000	Dec 23 07:00 PM
Halstead Michael	EVP and General Counsel	Dec 21	Option Exercise	16.38	176,863	2,897,494	176,863	Dec 23 07:02 PM
Halstead Michael	EVP and General Counsel	Dec 21	Sale	47.56	176,863	8,412,278	0	Dec 23 07:02 PM
Hineline Lawrence J.	SVP of Finance CFO	Dec 21	Sale	47.59	175,000	8,328,664	0	Dec 23 07:00 PM
Neumann Mark	EVP, Chief Commercial Officer	Oct 18	Sale	40.86	13,448	549,551	45,339	Oct 19 04:26 PM
Mates Sharon	Chairman, President & CEO	Oct 18	Sale	40.00	8,192	327,680	1,094,467	Oct 18 06:00 PM
Mates Sharon	Chairman, President & CEO	Oct 15	Option Exercise	2.84	1,075	3,053	1,102,659	Oct 18 06:00 PM
Mates Sharon	Chairman, President & CEO	Oct 15	Sale	40.00	40,392	1,615,680	1,101,584	Oct 18 06:00 PM
Mates Sharon	Chairman, President & CEO	Oct 14	Sale	40.00	1,416	56,640	1,141,976	Oct 18 06:00 PM
Mates Sharon	Chairman, President & CEO	Aug 23	Option Exercise	2.84	10,000	28,400	1,143,392	Aug 24 04:06 PM
MARCUS JOEL S	Director	Jun 14	Option Exercise	38.35	20,000	767,000	67,269	Jun 15 05:02 PM
MARCUS JOEL S	Director	Jun 14	Sale	42.27	18,289	773,076	48,980	Jun 15 05:02 PM
Alafi Christopher D	Director	May 28	Sale	40.12	38,843	1,558,381	95,000	May 28 06:00 PM
Alafi Christopher D	Director	May 27	Sale	40.01	8,482	339,365	133,843	May 28 06:00 PM
Alafi Christopher D	Director	May 24	Sale	40.47	26,575	1,075,490	142,325	May 25 06:02 PM
Alafi Christopher D	Director	May 21	Sale	40.00	1,100	44,000	168,900	May 25 06:02 PM
MARCUS JOEL S	Director	Mar 02	Option Exercise	26.58	20,000	531,600	87,519	Mar 04 05:43 PM
MARCUS JOEL S	Director	Mar 02	Sale	34.93	15,250	532,682	72,269	Mar 04 05:43 PM
Durgam Suresh K.	Chief Medical Officer	Feb 19	Sale	39.25	2,734	107,310	23,104	Feb 22 08:09 PM
Neumann Mark	EVP, Chief Commercial Officer	Feb 19	Sale	39.22	5,184	203,308	45,339	Feb 22 08:07 PM
Hineline Lawrence J.	SVP of Finance CFO	Feb 19	Sale	39.23	10,442	409,625	0	Feb 22 08:05 PM
Halstead Michael	EVP and General Counsel	Feb 19	Sale	39.24	11,139	437,133	0	Feb 22 08:03 PM
Mates Sharon	Chairman, President & CEO	Feb 19	Sale	39.23	27,847	1,092,436	1,133,392	Feb 22 08:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience